Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) CFO Sells 4,683 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $20.97, for a total transaction of $98,202.51. Following the completion of the sale, the chief financial officer owned 80,351 shares of the company’s stock, valued at $1,684,960.47. This trade represents a 5.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Howard Horn also recently made the following trade(s):

• On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.40, for a total transaction of $36,624.00.
• On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.70, for a total transaction of $190,884.30.
• On Monday, February 2nd, Howard Horn sold 3,061 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $23.56, for a total transaction of $72,117.16.

Ultragenyx Pharmaceutical Trading Up 4.8%

Shares of NASDAQ:RARE traded up $1.03 on Thursday, hitting $22.45. 1,771,183 shares of the company were exchanged, compared to its average volume of 2,452,838. The firm has a market capitalization of $2.21 billion, a P/E ratio of -3.84 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a 1-year low of $18.29 and a 1-year high of $42.37. The stock’s 50 day moving average price is $22.25 and its 200 day moving average price is $27.85.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). The firm had revenue of $207.28 million during the quarter, compared to analyst estimates of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. Ultragenyx Pharmaceutical’s revenue was up 25.5% on a year-over-year basis. During the same period in the previous year, the company earned ($1.39) earnings per share. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Ultragenyx Pharmaceutical by 14.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock worth $8,414,000 after purchasing an additional 29,984 shares in the last quarter. Creative Planning purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $454,000. American Century Companies Inc. purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at approximately $366,000. Russell Investments Group Ltd. lifted its stake in shares of Ultragenyx Pharmaceutical by 15.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 120,195 shares of the biopharmaceutical company’s stock valued at $4,370,000 after purchasing an additional 16,373 shares during the period. Finally, Elevation Point Wealth Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $55,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on RARE shares. Bank of America reduced their price objective on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, January 2nd. Guggenheim dropped their target price on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating on the stock in a research report on Monday, January 5th. Wells Fargo & Company cut their price target on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating on the stock in a report on Tuesday, December 30th. HC Wainwright reduced their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Finally, Jefferies Financial Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a research note on Tuesday, December 30th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $60.47.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Positive clinical readthrough: Ultragenyx’s experimental AAV8 gene therapy DTX301 (Enh3ance Phase‑3) has been reported to show favorable Phase‑3 results for OTC deficiency, reinforcing mid/long‑term commercial and value potential for the pipeline. This is a constructive catalyst for sentiment and valuation if further data and regulatory paths remain supportive. InsiderMonkey: DTX301 Phase‑3 Results
• Neutral Sentiment: Insider sale executed under 10b5‑1: CFO Howard Horn sold 4,683 shares on April 1 at an average $20.97 (≈$98.2k); his post‑trade holdings remain ~80,351 shares (a 5.51% reduction). The sale was pre‑arranged under a Rule 10b5‑1 plan, which lessens immediate governance concerns but can still be perceived negatively by some investors. SEC Filing: Insider Sale
• Negative Sentiment: Legal overhang — multiple class‑action notices: Several plaintiff law firms and shareholder services (Rosen, ClaimsFiler, Schall, Pomerantz, Levi & Korsinsky, Berger Montague, Kahn Swick & Foti, Bronstein Gewirtz & Grossman, etc.) have issued reminders about a securities‑fraud class action covering purchases between Aug 3, 2023 and Dec 26, 2025, with an April 6, 2026 lead‑plaintiff deadline. The proliferation of filings/solicitations signals potential litigation risk, possible settlement exposure, and near‑term negative press flow that can weigh on the stock. Representative notices: Rosen Law Notice ClaimsFiler Notice Schall Law Notice

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.